What is happening with GW Pharmaceuticals?
DUBLIN , May 5, 2021 /PRNewswire/ — Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”), a leader in the science, development and commercialization of cannabinoid-based prescription medicines.
Should I buy GW Pharmaceuticals stock?
GW Pharmaceuticals PLC(GWPH-Q) Rating A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.
How much is GW Pharmaceuticals worth?
Market cap: $6.81 Billion As of April 2022 GW Pharmaceuticals has a market cap of $6.81 Billion.
Who is buying GWPH?
A big merger at the intersection of the marijuana and pharmaceutical industries is one step closer to completion. On Friday, shareholders of GW Pharmaceuticals ( GWPH ) approved its acquisition by a subsidiary of Jazz Pharmaceuticals ( JAZZ 0.88% ), both companies announced in a joint press release.
Who bought Greenwich Pharmaceuticals?
plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or $6.7 billion net of GW cash.
Does GW Pharmaceuticals still exist?
You are now leaving the gwpharm.co.uk website. Please note that GW Pharmaceuticals is now part of Jazz Pharmaceuticals and you are being redirected to Jazz Pharmaceuticals’ privacy statement.
Why is GWPH stock down?
Shares of GW Pharmaceuticals PLC gwph slumped 12% Friday, after the company swung to a loss in the second quarter, hurt by the effect of the coronavirus pandemic.
Is GW Pharmaceuticals publicly traded?
In 2001, GW Pharmaceuticals listed on the Alternative Investment Market, the junior market of the London Stock Exchange. In May 2013, the company became dual-listed on the NASDAQ and AIM.
What is the ticker symbol for GW Pharmaceuticals?
GW Pharmaceuticals trades on the NASDAQ under the ticker symbol “GWPH.”
Is jazz stock a buy?
Jazz Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.
Who owns Jazz Pharmaceuticals?
Bruce C. Cozadd
The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA)….Jazz Pharmaceuticals.
|Key people||Bruce C. Cozadd (Chairman & CEO)|
|Brands||Xyrem Erwinaze Defitelio FazaClo FazaClo HD Luvox CR Prialt Vyxeos|
|Revenue||US$1.618 billion (2017)|
What does GW stand for in GW Pharmaceuticals?
|Founder||Geoffrey Guy Brian Whittle|
|Headquarters||Cambridge, United Kingdom|
|Key people||Justin Gover (CEO)|
|Products||Epidiolex (Epidyolex in Europe) Nabiximols (Sativex)|
What is GW Pharmaceuticals’ stock price and ticker symbol?
What is GW Pharmaceuticals’ stock symbol? GW Pharmaceuticals trades on the NASDAQ under the ticker symbol “GWPH.” What is GW Pharmaceuticals’ stock price today? One share of GWPH stock can currently be purchased for approximately $218.96.
Should you hold GW Pharmaceuticals (gwph) stock?
The consensus among Wall Street research analysts is that investors should “hold” GW Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GWPH, but not buy additional shares or sell existing shares.
How much does GW Pharmaceuticals make a year?
GW Pharmaceuticals has a market capitalization of $6.86 billion and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis. How many employees does GW Pharmaceuticals have? GW Pharmaceuticals employs 1,161 workers across the globe.
What’s GW Pharmaceuticals CEO approval rating on Glassdoor?
14 employees have rated GW Pharmaceuticals CEO Justin Gover on Glassdoor.com. Justin Gover has an approval rating of 80% among GW Pharmaceuticals’ employees. Who are some of GW Pharmaceuticals’ key competitors?